Acquisition & Worldwide Commercialization

Secura Bio is focused on developing and commercializing innovative therapies for patients with serious illnesses, particularly in the field of oncology. One of their key products is Duvelisib, which is currently undergoing clinical trials for various types of lymphomas, including relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Indolent Non-Hodgkin Lymphoma (iNHL). The clinical development of Duvelisib includes multicenter, open-label studies designed to evaluate its efficacy and safety through different dosing schedules and treatment regimens. These studies aim to measure outcomes such as overall response rates, progression-free survival, and overall survival, while also considering patient eligibility criteria based on specific lymphoma subtypes and prior treatment history.

In addition to Duvelisib, Secura Bio is exploring various areas of research interest, including combination therapies with other innovative treatments such as CAR T-cell therapies, bispecific antibodies, and immunotherapies. The company is also interested in real-world data and health economics to better understand the impact of their therapies. Their commitment to advancing treatment options for hematologic malignancies and solid tumors reflects a broader goal of improving patient outcomes through novel dosing strategies and therapeutic combinations.

United States

A diagnosis of a serious illness can change life in an instant and finding treatment options is key. At Secura Bio®, we see things differently. We develop and commercialize innovative medicines and life changing products for the patients that need them most.

Secura Bio

Company Details